Mahmoud Pouladi

Pouladi Mahmoud

Appointment(s)
  • Assistant Professor, Department of Medicine
Joint Appointment(s)
  • Associate Director, Translational Laboratory in Genetic Medicine, A*STAR
  • Principal Investigator, Translational Laboratory in Genetic Medicine, A*STAR
Academic Qualifications
  • PhD (Medical Genetics), University of British Columbia, Canada
  • MSc (Immunology), McMaster University, Canada
  • BSc (Molecular Biology), McMaster University, Canada
Research Interest(s)
  • Dementia
  • Huntington Disease
  • Fragile X Syndrome
  • Disease Modelling
  • Human Pluripotent Stem Cells
  • Target Discovery and Validation
Recent Publications
  • 1. Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A et al. 2017 Dec. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2(23). doi: 10.1172/jci.insight.95665.
  • 2. Chen MZ, Moily NS, Bridgford JL, Wood RJ, Radwan M, Smith TA, Song Z, Tang BZ, Tilley L, Xu X et al. 2017 Sep. A thiol probe for measuring unfolded protein load and proteostasis in cells. Nature Communications. 8:474. doi: 10.1038/s41467-017-00203-5.
  • 3. Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, Utami KH, Fidan K, Park DS, Malleret B et al. 2017 Jul. Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. Immunity. 47(1):183-+(22). doi: 10.1016/j.immuni.2017.06.017.
  • 4. Xu X, Tay Y, Sim B, Yoon S-I, Huang Y, Ooi J, Utami KH, Ziaei A, Ng B, Radulescu C et al. 2017 Mar. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports. 8(3):619-633. doi: 10.1016/j.stemcr.2017.01.022.
  • 5. Southwell AL, Skotte NH, Villanueva EB, Ostergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S et al. 2017 Mar. A novel humanizedmouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics. 26(6):1115-1132. doi: 10.1093/hmg/ddx021.